Genome express, the Centre Léon Bérard in Lyon and the Centre Jean Perrin in Clermont Ferrand has announced the signing of a three-way collaboration framework agreement to carry out the Mutacancer research program.
Mutacancer is a very high throughput sequencing program involving the mutational analysis of 300 gene candidates in human cancers. Specific cancers targeted are in particular breast, colon, lung, osteosarcoma and neuroblastoma.
Mutacancer will allow the identification of diagnostic and therapeutic targets while contributing to the understanding of critical molecular mechanisms and events.
The results of this research will be made available to other players in the healthcare sector with the long-term aim of improving patient care.
The three partners say they are also considering the possibility of a further agreement to market jointly services to the pharmaceutical industry.
For Genome express, the partnership is further proof of scientific interest from leading international experts in the company's achievements.
“The agreement with these two well-known cancer research centers is yet another recognition of Genome express's know-how and confirms its position as a high value-added partner in R&D, particularly in the field of oncology,” said Warren Barton, CEO of Genome express.
“We are delighted that the project, initiated by Prof Alain Puisieux, has come to fruition, and that we are working with his team and that of Prof Yves Jean Bignon to carry further forward the fight against cancer.”
The Léon Bérard and the Jean Perrin centers will have special access to Genome express's technology platforms as a result of this deal, and any discoveries will become the property of health establishments, while any advances in screening technology will belong to Genome express.
“We have already obtained very encouraging results and observed hitherto unreported mutations during feasibility studies,” said Prof Alain Puisieux from the Centre Léon Bérard.
“We were highly impressed by the speed with which GENOME express was able to customize its technological approach to meet Mutacancer requirements, that is to carry out high throughput screening of gene mutations. The collaboration is an excellent example of what academic and industry cooperation can bring.”
“This is the most important development for the Mutacancer project since France's National Cancer Institute gave it its blessing,” said Prof Yves Jean Bignon from the Centre Jean Perrin.
“We are excited to be part of this program and to contribute to the joint development of CLARA, the regional cancer network.”